Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

On the surface, the formula for weight loss seems simple: eat less and move more. But giving that advice to someone with ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

The surging popularity of GLP-1 drugs is beginning to obscure the health consequences if people stop taking them, physicians ...

Purchases of calorie-dense, processed items such as chips, baked goods and cookies were most affected, according to findings ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Nestlé released a similar announcement on September 18, 2024, revealing an entirely new line of GLP-1-friendly foods under ...

GLP-1 weight-loss drugs are cutting calories… and grocery bills, according to a new study from Cornell and Numerator.

MassHealth is transitioning coverage for anti-obesity drugs, designating Zepbound as the preferred option starting in January 2025, with Wegovy and Saxenda being discontinued for most adult members.